---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-110287"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2024-10-21T23:59:59+00:00"
generated_at: "2026-05-30T12:24:16.305998+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics regains Nasdaq compliance with $50M market value requirement

## Summary
- Received Nasdaq letter on Oct 21, 2024 confirming regained compliance with MVLS Requirement.
- Previously non-compliant as of July 11, 2024; had until Jan 7, 2025 to cure.
- Compliance now achieved; matter closed with no further action needed.
- Regained compliance ensures continued listing on The Nasdaq Global Market.

## SEC filing metadata
- accession: 0001104659-24-110287
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2024-10-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465924110287/0001104659-24-110287-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465924110287/tm2426597d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-110287
- JSON: https://secwatch.observer/filing/0001104659-24-110287.json
- Plain text: https://secwatch.observer/filing/0001104659-24-110287.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.